Aditxt business update with Amro Albanna, co-founder and CEO

Aditxt business update with Amro Albanna, co-founder and CEO

Associated equity: Aditxt

Edison Investment Research is terminating coverage on Aditxt. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Aditxt — 2 videos in collection

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. The company’s immune mapping technologies are designed to provide a personalised immune profile. Its immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies.

In this webinar, Aditxt’s CEO, Amro Albanna, is joined by Jason Kolbert, a research analyst at Dawson James. Jason asks Amro about overall business updates and milestones and the company’s acquisition strategy.

You may also be interested in these:


Aditxt: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free